Plain-English translation of NCT07673029 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called works as well as or better than an existing breast cancer treatment () for people with advanced HER2-positive breast cancer. Both medications are given through an IV every three weeks. The study will help doctors understand if this new treatment is a good option for patients whose cancer has not responded adequately to earlier therapies.
Some patients with advanced HER2-positive breast cancer stop responding well to standard treatments over time. This medication aims to provide another effective option for these patients and potentially offer better results or fewer side effects than current alternatives.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either or , given as an intravenous infusion every three weeks. You will visit the clinic regularly for infusions and monitoring visits, where doctors will check your health, do blood work, and perform imaging scans to see how you are responding to the medication. The trial involves about 228 patients across multiple hospitals and clinics, and your doctors will closely track any side effects and how well the treatment is working.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China